The diagnostics sector is experiencing rapid transformation – with molecular diagnostics, point-of-care testing, AI-powered digital pathology, and liquid biopsy all creating new market entry opportunities alongside the continued growth of traditional laboratory diagnostics. Diagnostics companies, pathology laboratory operators, diagnostic equipment manufacturers, and clinical laboratory information system providers are all evaluating new market entry opportunities across Southeast Asia, South Asia, and the Gulf. GreyRadius helps diagnostics businesses validate clinical demand, navigate regulatory requirements, and raise capital.
Why now? Healthcare infrastructure investment is driving diagnostics market growth – new hospital construction, national health insurance expansion, and disease burden management programmes are all creating funded diagnostics demand. Early disease detection programmes in the Gulf and Southeast Asia are creating specific demand for advanced molecular and cancer diagnostics.
Diagnostics market in Southeast Asia is growing at 9% annually – driven by hospital expansion, NHI inclusion of diagnostic tests, and rising patient awareness of preventive diagnostics.
Point-of-care diagnostics is the fastest-growing segment – rapid tests for infectious diseases, chronic disease management, and STIs are achieving high adoption in primary care and community health settings.
AI digital pathology is transforming histopathology – AI-assisted tissue analysis is reducing pathologist workload and improving diagnostic accuracy, creating significant commercial opportunities in markets with pathologist shortages.
Genetic and genomic diagnostics are expanding rapidly in affluent markets – consumer genomics, pharmacogenomics, and hereditary cancer screening are all growing in the Gulf, Singapore, and urban India.
If you recognise your situation below, we can help.
Diagnostics market demand and channel assessment
You need to understand test volume potential, ordering physician behaviour, and the competitive diagnostic landscape in your target market.
Regulatory registration pathway
You need to understand IVD registration requirements, performance data requirements, and approval timelines in your target market.
Laboratory and hospital partner identification
You need to identify reference laboratories, hospital laboratory networks, and diagnostic chains as potential distribution partners or customers.
GTM for diagnostic equipment or reagents
You have a diagnostic analyser, reagent, or IVD kit and need a go-to-market strategy covering laboratory and hospital acquisition.
Raising capital for a diagnostics venture
You are raising investment and need a pitch book grounded in test volume data and market sizing.
Competitive intelligence
You need to understand how competing diagnostic companies are positioned and winning laboratory contracts in your target market.
Every engagement is grounded in primary research and delivers a measurable outcome.
Validate clinical demand and market opportunity for diagnostic products in a new market. Covers physician and laboratory interviews, regulatory mapping, competitive analysis, and a Go/Defer/Kill recommendation.
Learn more →Full financial and operational feasibility for diagnostics investments. Covers test volume modelling, distribution cost structure, regulatory compliance cost, and bankable financial projections.
Learn more →End-to-end market entry for diagnostics companies. Regulatory registration pathway, laboratory and hospital partner identification, and first-laboratory or first-hospital acquisition.
Learn more →Embedded GTM team for diagnostic equipment and IVD companies. Laboratory and hospital outreach, reference laboratory pipeline, and first-revenue milestone tracking.
Learn more →Investor-ready pitch books for diagnostics ventures. Test-volume-validated market sizing, regulatory pathway clarity, and investor identification.
Learn more →AI use-case prioritisation in diagnostics – from automated image analysis and result interpretation to laboratory workflow optimisation and predictive test ordering.
Learn more →80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Healthcare · Market Entry
Healthcare · GTM Execution
Healthcare · Assessment
All three. We work with IVD manufacturers on market entry, laboratory operators on market entry and GTM, and digital diagnostics companies on market entry and fundraising.
Southeast Asia, South Asia, and the Gulf – markets with significant diagnostic demand growth.
Typically 8–10 weeks given the complexity of regulatory mapping and clinical demand research.
Yes. Laboratory partner identification and initial commercial conversations are part of our market entry execution service.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Southeast Asia, South Asia, Gulf.
